Fiche société
Lucid Diagnostics, Inc.
Traitements, essais et publications liés.
Traitements4programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| EsoGuardThe study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines. | SEP | NA | À vérifier | United States, Spain | À vérifier |
| EsoGuard (lab assay)The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC) | SEP | NA | À vérifier | United States, Netherlands | À vérifier |
| EsoGuard (lab assay)The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC) | SEP | NA | À vérifier | United States, Netherlands | À vérifier |
| EsoGuardThe study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines. | SEP | NA | À vérifier | United States, Spain | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| EsoGuard | SEP | NA | NCT04293458 | ESOGUARDBE1 — Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE | COMPLETED |
| EsoGuard (lab assay) | SEP | NA | NCT04295811 | ESOGUARDBE2 — Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC | UNKNOWN |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| EsoGuard | Nonendoscopic Detection of Barrett's Esophagus on Patients Without Gastroesophageal Reflux Disease Symptoms. | The American journal of gastroenterology | ||
| EsoGuard | Pilot study of EsoCheck/EsoGuard for detecting Barrett's esophagus in high-risk patients undergoing hiatal hernia repair. | Surgical endoscopy | ||
| EsoGuard | Swallowing the Future of Cancer Prevention: Could EsoGuard Revolutionize the Fight Against Esophageal Cancer? | Gastro hep advances |